Walgreens Boots Alliance Thursday reported a narrower-than-expected $178 million loss in its third … More quarter as the struggling pharmacy chain nears the end of its long run as a publicly traded company, the drugstore chain said June 26,. 2025. In this photo is an aerial view of a sign posted outside of a Walgreens store on January 04, 2024 in San Pablo, California. (Photo by Justin Sullivan/Getty Images)
Getty Images
Walgreens Boots Alliance Thursday reported a narrower-than-expected $175 million loss in its third quarter as the struggling pharmacy chain nears the end of its long run as a publicly traded company.
Walgreens fiscal third quarter results for the period ending May 31 of this year come as the company works on completing its sale to the investment firm Sycamore Partners for more than $10 billion. That deal, announced in early March, faces a special meeting of shareholders on July 11 to vote on approving the sale
Though sales rose 7% to $39 billion, the company lost $175 million, 鈥渁 decrease of $519 million compared to net earnings of $344 million鈥 in the year-ago period thanks largely to 鈥減rior year after-tax gains related to fair value adjustments on variable prepaid forward derivatives and a partial sale of the company’s equity method investment in Cencora, and higher tax expense in the current quarter.鈥 Cencora is the large drug distributor that Walgreens owns a minority stake in and has been gradually selling.
The Sycamore deal, which pays $11.45 per share 鈥 29% above the December stock price 鈥 comes after years of Walgreens鈥 pharmacy closings and plummeting stock in part due to a disastrous rollout of clinics attached to stores.
Walgreens chief executive officer Tim Wentworth said third quarter results 鈥渞eflect continued improvement in our U.S. Healthcare segment and benefits from our cost savings initiatives, while we continued to see weakness in our U.S. front-end sales.鈥
MORE FOR YOU
Walgreens said U.S. Retail Pharmacy segment sales rose nearly 8% to $39.7 billion compared to the year-ago quarter. Within that business, however, retail sales decreased 5% and that spilled onto adjusted operating income which decreased 30% to to $350 million from $501 million in the year-ago quarter.
鈥淲e remain focused on our turnaround plan, which will require time, disciplined focus and a balanced approach to manage future cash needs with investments necessary to navigate an evolving pharmacy and retail environment,鈥 Wentworth said.
Sycamore, a private equity firm specializing in consumer, distribution and retail-related investments, also agreed to 鈥渙ne non-transferable right” to receive up to $3 in cash per Walgreens Boots Alliance share 鈥渇rom the future monetization of WBA鈥檚 debt and equity interests in VillageMD, which includes the Village Medical, Summit Health and CityMD businesses,鈥 the companies said of Walgreens鈥 primary care businesses. The total value of the deal, including the $10 billion in equity value, is more than $23 billion when debt and other items are included, the companies said.
Walgreens third quarter results were much improved over its second quarter when the company in March reported a $2.8 billion loss thanks to a large impairment charge related to its struggling doctor-staffed clinic investment in VillageMD.
The Sycamore deal comes after Walgreens, which had a market value of more than $100 billion a decade ago, undertook the failed VillageMD in-store clinic rollout that led it to close hundreds of stores to reduce debt and stem financial losses.
Under former chief executive Roz Brewer, Walgreens spent billions of dollars investing in and operating physician-staffed clinic operator VillageMD.
Walgreens invested more than $6 billion in VillageMD under Brewer to take a controlling stake, but the company has already scaled back dramatically on the expansion of doctor practices and clinics the company opened. In 2020, Walgreens said it planned to open 500 to 700 鈥淰illage Medical at Walgreens鈥 physician-led primary care clinics in more than 30 U.S. markets over five years, with the 鈥渋ntent to build hundreds more thereafter.鈥
For the nine month period ended May 31, Walgreens has lost more than $3.2 billion, or $3.81 per share. That compares with $5.6 billion, or $6.53 in the year-ago period.
Editorial StandardsReprints & Permissions